AzTrials
AzTrials

MorbidityPhase 3NCT07297264

Betamethasone and Complications of Lower Third Molar Surgery

A Phase 3 study testing Betamethasone and normal saline in people with Morbidity and Third Molars Extraction, run by Shehab Ahmed Hamad at 1 site in Iraq.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Pain, swelling, and trismus are common sequalae of surgical removal of impacted third molars. The aim of this study is to evaluate effect of local administration of betamethasone, into the pterygomandibular space, on these sequalae Read more about this study

Who is it for?
Ages 18 to 35 years
What is being tested?
Betamethasone and normal saline
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
40 participants
Where
1 siteIraq
Study dates
3 Jan 2022to 26 Mar 2023
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 35 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • healthy
  • no infection
  • no pain
  • no limitation of mouth opening
  • symmetrical bilateral impacted third molars (Mesioangular, CLASS II, Position B

Who cannot join

  • Infection
  • systemic disease
  • smokers
  • operation time exceeding 30 minutes

Trial locations and contacts

1 site in 1 country.

Iraq1 site
  • Shehab Ahmed Hamad

    Erbil, 00441

Other trials in Iraq

About this study

Official title: Effect of Betamethasone Injection Into the Pterygomandibular Space on Postoperative Sequelae of Impacted Lower Third Molar Surgery: A Randomized, Double-blind, Placebo-controlled Clinical Trial With a Split-mouth Design

Pain, swelling, and trismus are common sequalae of surgical removal of impacted third molars. The aim of this study is to evaluate effect of local administration of betamethasone, into the pterygomandibular space, on these sequalae

Read the detailed description

A prospective, single center, double-blind, randomized controlled design study was conducted between January 2022 and February 2023, in the department of oral and maxillofacial surgery, Rizgary teaching hospital, Erbil, Iraq. The participants were patients presented for the surgical removal of bilateral symmetrical impacted lower third molars. To achieve 95% power, a sample size of 40 patients with bilateral impacted third molars was required.

The study was approved by the Ethical Committee of the institutional board and was conducted in accordance with the guidelines of the World Medical Association Declaration of Helsinki (1964) and its seventh amendment (2013) and to the Consolidated Standards of Reporting Trials (CONSORT) (Figurec1). The objectives of the study, as well as the risks and benefits were explained to the patients and those who agreed to participate have signed a consent form.

The inclusion criteria of the study were: individuals of both genders aging between 18 and 35 years, classified as ASA I according to the American Society of Anesthesiologists, and who have symmetrical bilateral impacted mandibular third molar detected by a panoramic radiograph. Impacted teeth categorized as mesiaoangular (Winter classification) and class II position B (Pell and Gregory classification) were included. The patients had no infection, pain, trismus, and swelling at the time of surgery.

Patients who are smokers, with pericoronitis, active infection, systemic disorders, on long term steroids, pregnant and lactating women were excluded. Patients were also precluded if they had taken analgesics 24 hours before- and antibiotics one week before the surgery, and if the surgical procedure exceeded 30 minutes or if more than three cartridges of local anaesthesia were used during the procedure.

By implementing the split mouth model, each participant underwent two surgical procedures, with an interval of at least 4 weeks between them. Prior to the first procedure, randomization of the first side to be operated (right or left) was performed using the "heads or tails" technique using a coin, where the head represented the right side and tails the left side.

The study group (group I) received 1 ml (6 mg) of betamethasone (CKOÇAK FARMA, Turkey) injection to the pterygomandibular space. Each ml contains 3.0 mg betamethasone acetate and 3.0 mg betamethasone sodium phosphate. The control group (group II) received a corresponding volume of normal saline injected into the pterygomandibular space. To ensure blinding of the study, the solution was injected by a third person, who is not directly involved in the surgery nor in the postoperative visits.

Impacted mandibular third molar surgery was performed under local anesthesia, using 2% lidocaine hydrochloride with 1:80,000 concentration of adrenaline. Inferior alveolar nerve, lingual and buccal nerve block technique were performed. After profound anesthesia was achieved, the betamethasone, or the sham solution, was injected into the pterygomandibular space using 3 ml disposable plastic syringe and gauge 25 hypodermic needle. A standard Ward's incision was designed and the mucoperiosteal fap was reflected to expose the surgical site. A lingual flap was reflected, only when deemed to be necessary. Bone guttering was made using round No.8 and straight fissure carbide bur (no. 703) bur, under copious saline irrigation. The tooth was sectioned or removed as whole. It was then luxated and delivered using elevators and forceps. The socket was thoroughly irrigated with normal saline solution done, after the rough bone margins were trimmed and finally the wound was closed with 3-0 Vicryl suture. The duration of surgery was measured from the time of incision to placement of the last suture.

The patient was given the usual postoperative instructions, including ice pack application to the operated side for 20 minutes, with 20-minute intervals between applications, for the first day. The patient was advised to consume cold liquid diet in the first day, and soft diet for the next 5 days. In addition, twice daily mouth wash with chlorhexidine 0.12% for 5 days, starting the day after surgery. Patients were given three days course of broad-spectrum antibiotic (amoxicillin 500 mg every eight hours or clindamycin 300 mg every eight hours if a penicillin allergy existed) and paracetamol 1g as a rescue analgesic.

The Facial swelling and the degree of trismus was recorded by the same operator, preoperatively and on the first, third, and seventh postoperative days. The pain was recorded by the patient, at 8:00 am, using visual analogue scale (VAS) at 1-5 postoperative days. . The patients rated pain on a 10-cm VAS, from no pain (0) to the most severe pain (10). Number of analgesic tablets consumed by the patients ,during the first five postoperative days, was also calculated. Flexible tape was used for measuring the following facial distances: gonion-lip commissure, gonion-external canthus of the eye, tragus-lip commissure, tragus-soft tissue pogonion. The sum of the preoperative measurements was considered as a baseline for the side of the face being assessed. Subtracting the preoperative measurement from the postoperative one indicated the amount of facial swelling. The degree of trismus was assessed by measuring the distance between the incisal edges of the upper and lower central incisors, on maximum mouth opening, using a digital vernier Statistical analyses was performed using the statistical package SPSS software 25.0. Comparisons between the groups was carried out using an independent t test. The significance level was set at P < 0.05.

Being tested
Betamethasone, normal saline

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BetamethasoneDrug

    Also called Betamethasone injection ino the pterygomandibular space

    The study group (group I) received 1 ml (6 mg) of betamethasone (CKOÇAK FARMA, Turkey) injection to the pterygomandibular space. Each ml contains 3.0 mg betamethasone acetate and 3.0 mg betamethasone sodium phosphate

  • normal salineDrug

    normal saline

Study groups in NCT07297264
Study groupRoleWhat they receive
betamethasone treated sideExperimentalBetamethasone was administered into the pterygomandibular space immediately before surgery
Receives: Drug: Betamethasone
Control sidePlacebo comparatornormal saline was administered into the pterygomandibular space immediately before surgery
Receives: Drug: normal saline

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Postoperative pain was assessed by patient self-report using a visual analogue scale (VAS; 0-10), where 0 indicated no pain and 10 indicated the worst imaginable pain.

    postoperative pain assessed by the patient on VAS pain score

    Measured: Pain scores were recorded immediately after surgery and daily for the first five days

Secondary outcomes (2)
  1. trismus

    degree of maximum mouth opening measured between the maxillary and mandibular central incisors using a digital vernier

    Measured: Trismus was measured on the first, third, and seventh postoperative days

  2. Facial swelling

    Flexible tape was used for measuring the following facial distances: gonion-lip commissure, gonion-external canthus of the eye, tragus-lip commissure, tragus-soft tissue pogonion. The sum of the preoperative measurements was considered as a baseline for the side of the face being assessed. Subtracting the preoperative measurement from the postoperative one indicated the amount of facial swelling.

    Measured: Facial swelling was measured on the first, third, and seventh postoperative days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Dec 2025
  2. Study start3 Jan 2022
  3. Primary completion21 Feb 2023
  4. Study completion26 Mar 2023

Why it stopped: There was a change in the protocol of the study

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Crossover
Masking
Single blind
Who is masked
Participant
Enrolment
40 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07297264
Sponsor's protocol ID
Betamethasone in MTM
Status last verified
Dec 2025
First submitted
19 Apr 2023
Last updated
22 Dec 2025
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Betamethasone and normal saline in people with Morbidity and Third Molars Extraction, run by Shehab Ahmed Hamad at 1 site in Iraq.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 22 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Iraq. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was stopped early (reason given: There was a change in the protocol of the study). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Postoperative pain was assessed by patient self-report using a visual analogue scale (VAS; 0-10), where 0 indicated no pain and 10 indicated the worst imaginable pain. (time frame: Pain scores were recorded immediately after surgery and daily for the first five days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in